Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Tampa, Florida

Cancer biologic therapy trials in Tampa, FL

53 cancer biologic therapy studies are recruiting participants at sites in Tampa as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Tampa at a glance

  • 53 studies are recruiting at a site in Tampa.
  • By phase: Early Phase 1 (1), Phase 1 (8), Phase 1/2 (5), Phase 2 (19), Phase 2/3 (2), Phase 3 (18).
  • By sponsor: industry (23), university, hospital or other (18), government (12).
  • By research area: Lymphoma (18), Lung Cancer (16), Breast Cancer (12), Melanoma (4), Prostate Cancer (3).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Tampa

Basic details from each study's public record (the 30 most recently updated of 53). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT03606967 · updated
  2. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Saint Joseph's Hospital/Children's Hospital-Tampa
    Registry record
    NCT06058377 · updated
  3. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Saint Joseph's Hospital/Children's Hospital-Tampa
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Lung cancer studies recruiting in Tampa

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT06498635 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Moffitt Cancer Center
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    James A. Haley Veterans Affairs Hospital · Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus
    Registry record
    NCT06096844 · updated
  4. A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Moffitt Cancer Center ( Site 0021)
    Registry record
    NCT07221474 · updated
  5. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Obsidian Therapeutics, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06060613 · updated
  6. Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    CatalYm GmbH
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07098988 · updated
  7. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06031688 · updated
  8. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06616584 · updated
  9. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Florida Cancer Specialists
    Registry record
    NCT07222566 · updated
  10. Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    H. Lee Moffitt Cancer Center and Research Institute
    Study site
    Moffitt Cancer Center
    Registry record
    NCT05681780 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Tampa

  1. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07164443 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Melanoma studies recruiting in Tampa

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06743126 · updated
  2. A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT04511013 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Tampa, FL on ClinicalTrials.gov.

Lymphoma studies recruiting in Tampa

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Saint Joseph's Hospital/Children's Hospital-Tampa
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT06337318 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Tampa General Hospital ( Site 0134)
    Registry record
    NCT06717347 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Saint Joseph's Hospital/Children's Hospital-Tampa · Tampa General Hospital
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Saint Joseph's Hospital/Children's Hospital-Tampa · Tampa General Hospital
    Registry record
    NCT05675410 · updated
  6. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07015242 · updated
  7. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07188558 · updated
  8. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06500273 · updated
  9. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Saint Joseph's Hospital/Children's Hospital-Tampa
    Registry record
    NCT06124157 · updated
  10. Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06015880 · updated
  11. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    • Phase 2
    • Ages 1 to 60
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    Moffitt Cancer Center
    Registry record
    NCT03970096 · updated
  12. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    • Phase 1
    • Ages 12 to 78
    • All sexes
    Sponsor
    Orca Biosystems, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT03802695 · updated
  13. A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

    • Phase 2
    • From 6 months
    • All sexes
    Sponsor
    Allotera Therapeutics
    Study site
    H. Lee Moffitt Cancer Center and Research Institute Hospital
    Registry record
    NCT06514794 · updated
  14. Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    H. Lee Moffitt Cancer Center and Research Institute
    Study site
    Moffitt Cancer Center
    Registry record
    NCT05757219 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Tampa, FL on ClinicalTrials.gov.

Ask about studies near Tampa

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call